InvestorsHub Logo
Followers 276
Posts 32697
Boards Moderated 0
Alias Born 11/14/2013

Re: hoffmann6383 post# 545976

Thursday, 12/08/2022 3:47:08 PM

Thursday, December 08, 2022 3:47:08 PM

Post# of 699716
Did you notice Dr. Stupp didn’t really critique the rGBM results? One of the advantages for DCVax-l in the recurrent trial is that there was no Temodar to interfere with t-cell behavior**. It also doesn’t infringe on his ego, because Temodar is not considered a salvage therapy.

In fact, DCVax-l can rehabilitate t-cell numbers and effectiveness after Temodar therapy is stopped.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News